Comparative Evaluation Of Quality Of Life In Patients Of Vernal Keratoconjunctivitis Treated With Bepotastine Besilate Versus Olopatadine And Ketorolac Combination In Eye Department At Tertiary Care Hospital In Indian Population

ABSTRACT

Ocular itching and redness adversely affect the quality-of-life of vernal keratoconjunctivitis (VKC) patients. The objective of thisstudy was to evaluate changes in VKC patient's quality-of-life (QOL). The present study was prospective, open label,randomized, comparative clinical study. Hundred patients of vernal keratoconjunctivitis between 6 to 20 years of age of eithersex willing to give informed consent were enrolled in the study. In Group A, 50 patients received Bepotastine besilate (0.15%)eye drops twice daily for 8 weeks whereas in Group B, 50 patients received Olopatadine (0.2%) and Ketorolac (0.4%)combination eye drops twice daily for 8 weeks. The Quality of Life Questionnaire (QUICK) is a reliable and validated which wasassessed at baseline and at the time of follow up at 8 weeks. QUICK Questionnaire scores range from 30 to 90 with higher valuesrepresenting greater impairment. A decrease in QUICK Questionnaire score is clinically meaningful to the patients.The results showed that after the 2 months of drug therapy, patients in both the groups showed decrease in the quality of lifescoring of VKC. However, there was no statistically significant difference between the two treatment groups at 8th week. It maybe concluded that both bepotastine besilate versus olopatadine and Ketorolac combination ophthalmic solutions were found to beeffective in alleviating the clinical symptoms and signs of VKC. Hence, improving the quality of life of VKC patients.Keywords Mast cell stabilizer, Topical NSAIDs, Newer H1-antihistaminics, Vernal keratoconjunctivitis, Quality of life